ATE437641T1 - Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis - Google Patents

Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis

Info

Publication number: ATE437641T1
Authority: AT; Austria
Prior art keywords: amyloid; microgliosis; reducing; animals; neurotoxicity
Prior art date: 2003-05-15

Application number

AT04752432T

Other languages

English (en)

Inventor

Michael Mullan

Daniel Paris

Original Assignee

Roskamp Res Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-15

Filing date

2004-05-17

Publication date

2009-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437641(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-17 Application filed by Roskamp Res Llc filed Critical Roskamp Res Llc

2009-08-15 Application granted granted Critical

2009-08-15 Publication of ATE437641T1 publication Critical patent/ATE437641T1/de

Links

206010029350 Neurotoxicity Diseases 0.000 title abstract 3
206010044221 Toxic encephalopathy Diseases 0.000 title abstract 3
230000007388 microgliosis Effects 0.000 title abstract 3
230000007135 neurotoxicity Effects 0.000 title abstract 3
231100000228 neurotoxicity Toxicity 0.000 title abstract 3
230000003941 amyloidogenesis Effects 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
241001465754 Metazoa Species 0.000 abstract 4
238000000034 method Methods 0.000 abstract 4
208000024827 Alzheimer disease Diseases 0.000 abstract 3
102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 3
108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 3
FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 abstract 3
230000003942 amyloidogenic effect Effects 0.000 abstract 3
230000002490 cerebral effect Effects 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
229960005366 nilvadipine Drugs 0.000 abstract 3
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
208000030886 Traumatic Brain injury Diseases 0.000 abstract 2
230000006933 amyloid-beta aggregation Effects 0.000 abstract 2
230000001537 neural effect Effects 0.000 abstract 2
210000000130 stem cell Anatomy 0.000 abstract 2
230000009529 traumatic brain injury Effects 0.000 abstract 2
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 abstract 1
229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
239000000480 calcium channel blocker Substances 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicinal Preparation (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT04752432T 2003-05-15 2004-05-17 Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis ATE437641T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47069403P	2003-05-15	2003-05-15
PCT/US2004/015417 WO2004110354A2 (en)	2003-05-15	2004-05-17	Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis

Publications (1)

Publication Number	Publication Date
ATE437641T1 true ATE437641T1 (de)	2009-08-15

Family

ID=33551420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04752432T ATE437641T1 (de)	2003-05-15	2004-05-17	Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis

Country Status (10)

Country	Link
US (1)	US7732467B2 (de)
EP (1)	EP1628663B1 (de)
JP (1)	JP4971794B2 (de)
CN (1)	CN100444840C (de)
AT (1)	ATE437641T1 (de)
CA (1)	CA2525970C (de)
DE (1)	DE602004022284D1 (de)
DK (1)	DK1628663T3 (de)
ES (1)	ES2334029T3 (de)
WO (1)	WO2004110354A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060188938A1 (en) *	2005-01-07	2006-08-24	Mullan Michael J	Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
ES2374716T3 (es) *	2005-04-15	2012-02-21	Research & Innovation S.P.A.	Método para prevenir, retrasar o revertir la deposición anormal de amiloide.
CA2644240A1 (en) *	2006-03-01	2007-09-13	Roskamp Research, Llc	Compounds for inhibiting beta-amyloid production
US20100119599A1 (en) *	2006-12-08	2010-05-13	Archer Pharmaceuticals, Inc.	Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
US8709394B2 (en) *	2007-09-28	2014-04-29	Ndsu Research Foundation	Antimicrobial polysiloxane materials containing metal species
CN101883564B (zh) *	2007-10-05	2013-10-16	阿尔茨海默病学会美国公司	使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
US20100093810A1 (en) *	2007-10-05	2010-04-15	Alzheimer's Institute Of America, Inc.	Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
WO2009046338A1 (en) *	2007-10-05	2009-04-09	Roskamp Research Llc	Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer
CA2761298A1 (en) *	2009-05-15	2010-11-18	The University Of Kentucky Research Foundation	Treatment of mci and alzheimer's disease
EP2311823A1 (de) *	2009-10-15	2011-04-20	AC Immune S.A.	2,6-Diaminopyridinverbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloidproteinen oder zur Behandlung von Augenkrankheiten
KR20140128229A (ko)	2013-04-26	2014-11-05	한국과학기술연구원	체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4338322A (en)	1975-07-02	1982-07-06	Fujisawa Pharmaceutical Co., Ltd.	1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS6038322A (ja)	1983-08-11	1985-02-27	Fujisawa Pharmaceut Co Ltd	ジヒドロピリジンａ物質含有易溶性固形製剤
JPS61129140A (ja)	1984-11-27	1986-06-17	Nitto Electric Ind Co Ltd	医薬組成物
GB8431119D0 (en)	1984-12-10	1985-01-16	Fujisawa Pharmaceutical Co	Anti-arteriosclerotic composition
US4940556A (en)	1986-01-30	1990-07-10	Syntex (U.S.A.) Inc.	Method of preparing long acting formulation
DE3877630T2 (de)	1987-06-12	1993-06-03	American Cyanamid Co	Transkutane verabreichung von pharmazeutika.
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US5114946A (en)	1987-06-12	1992-05-19	American Cyanamid Company	Transdermal delivery of pharmaceuticals
US5045553A (en)	1987-06-24	1991-09-03	Fujisawa Pharmaceutical Company, Ltd.	Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4820720A (en)	1987-08-24	1989-04-11	Alza Corporation	Transdermal drug composition with dual permeation enhancers
US5160734A (en)	1987-11-25	1992-11-03	American Cyanamid Company	Sustained release delivery system for substituted dihydropyridine calcium channel blockers
ATE76292T1 (de)	1987-11-25	1992-06-15	American Cyanamid Co	System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridincalciumantagonisten.
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP3479532B2 (ja)	1989-03-31	2003-12-15	ザ・チルドレンズ・メディカル・センター・コーポレーション	エイズの痴呆症、脊髄障害および失明の治療
JP2867462B2 (ja)	1989-09-12	1999-03-08	藤沢薬品工業株式会社	経皮吸収用製剤
JPH03117658A (ja)	1989-09-29	1991-05-20	Mazda Motor Corp	外燃式ロータリピストンエンジン
JP2920956B2 (ja)	1989-10-06	1999-07-19	藤沢薬品工業株式会社	ニルバジピン含有持続性錠剤
EP0557290A1 (de)	1990-08-23	1993-09-01	The Children's Medical Center Corporation	Behandlung von aids-assoziierter dementia, myelopathie, peripherer neuropathie und sehverlust
WO1993005770A1 (fr)	1991-09-20	1993-04-01	Fujisawa Pharmaceutical Co., Ltd.	Preparation a longue duree d'action
JPH05139974A (ja)	1991-11-26	1993-06-08	Fujisawa Pharmaceut Co Ltd	ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
DE4141646A1 (de)	1991-12-17	1993-06-24	Klinge Co Chem Pharm Fab	Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung
US5340591A (en)	1992-01-24	1994-08-23	Fujisawa Pharmaceutical Co., Ltd.	Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4229805A1 (de)	1992-09-07	1994-03-24	Werner E G Prof Dr Mueller	Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden
CA2125251C (en)	1993-06-07	2005-04-26	Yoshiyuki Inada	A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en)	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
US6334997B1 (en)	1994-03-25	2002-01-01	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
EP0911027A4 (de)	1996-04-26	2000-11-29	Fujisawa Pharmaceutical Co	Mittel die dihydropyridine enthalten zur verbesserung der durchblutung der augenumgebenden gewebe
US6271259B1 (en) *	1996-05-07	2001-08-07	Ito En, Ltd.	Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death
KR100222306B1 (ko)	1996-11-20	1999-10-01	이병언	닐바디핀 속효성 고형제제 및 이의 제조방법
WO1999063992A1 (en)	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Novel calcium channel drugs and uses
WO1999064045A1 (en)	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Novel therapeutic agents for membrane transporters
ES2289814T3 (es)	1998-07-10	2008-02-01	Novartis Pharma Ag	Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio.
WO2001064250A1 (en)	2000-03-03	2001-09-07	Fujisawa Pharmaceutical Co., Ltd.	Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof
NZ521853A (en)	2000-04-11	2003-11-28	Sankyo Co	Stabilized pharmaceutical compositions containing a calcium blocker
JP2001335483A (ja)	2000-05-30	2001-12-04	Nichiko Pharmaceutical Co Ltd	ニルバジピン含有製剤
WO2002009761A2 (en)	2000-07-27	2002-02-07	Pharmacia Corporation	Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP3968687B2 (ja)	2000-09-13	2007-08-29	東和薬品株式会社	易吸収性ニルバジピン錠
JP3470096B2 (ja)	2000-09-19	2003-11-25	沢井製薬株式会社	ニルバジピン含有易溶性固形製剤およびその製造法
KR20030059351A (ko)	2000-12-19	2003-07-07	메르크 파텐트 게엠베하	티에노피리미딘 및 항혈전제, 칼슘 길항제,프로스타글란딘 또는 프로스타글란딘 유도체를 포함하여이루어지는 약제학적 조성물
CA2431077A1 (en)	2000-12-19	2002-06-27	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
US7083642B2 (en)	2000-12-22	2006-08-01	Avantec Vascular Corporation	Delivery of therapeutic capable agents
CA2333494A1 (en)	2001-02-01	2002-08-01	Vasogen Ireland Limited	Blood brain barrier modulation
DE60216275T2 (de) *	2001-05-25	2007-06-21	Schering Corp.	Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
AU2003298514A1 (en)	2002-05-17	2004-05-04	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
TW200306799A (en)	2002-05-17	2003-12-01	Novartis Ag	Combination of organic compounds
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
BR0310084A (pt)	2002-05-17	2005-02-15	Novartis Ag	Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
JP2003146878A (ja)	2002-11-22	2003-05-21	Sawai Pharmaceutical Co Ltd	ニルバジピン含有易溶性固形製剤およびその製造法
WO2004058239A1 (en) *	2002-12-24	2004-07-15	Neurochem (International) Limited	Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050031651A1 (en)	2002-12-24	2005-02-10	Francine Gervais	Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2004002460A (ja)	2003-07-29	2004-01-08	Towa Yakuhin Kk	易吸収性ニルバジピン錠の製造法

2004
- 2004-05-17 WO PCT/US2004/015417 patent/WO2004110354A2/en not_active Ceased
- 2004-05-17 ES ES04752432T patent/ES2334029T3/es not_active Expired - Lifetime
- 2004-05-17 EP EP04752432A patent/EP1628663B1/de not_active Expired - Lifetime
- 2004-05-17 JP JP2006533144A patent/JP4971794B2/ja not_active Expired - Lifetime
- 2004-05-17 CN CNB2004800171974A patent/CN100444840C/zh not_active Expired - Fee Related
- 2004-05-17 CA CA2525970A patent/CA2525970C/en not_active Expired - Fee Related
- 2004-05-17 US US10/847,630 patent/US7732467B2/en active Active
- 2004-05-17 DE DE602004022284T patent/DE602004022284D1/de not_active Expired - Lifetime
- 2004-05-17 DK DK04752432.7T patent/DK1628663T3/da active
- 2004-05-17 AT AT04752432T patent/ATE437641T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2007501277A (ja)	2007-01-25
CA2525970A1 (en)	2004-12-23
ES2334029T3 (es)	2010-03-04
CN1809352A (zh)	2006-07-26
CN100444840C (zh)	2008-12-24
HK1092358A1 (en)	2007-02-09
EP1628663A2 (de)	2006-03-01
WO2004110354A2 (en)	2004-12-23
US20050009885A1 (en)	2005-01-13
EP1628663B1 (de)	2009-07-29
EP1628663A4 (de)	2006-05-24
US7732467B2 (en)	2010-06-08
WO2004110354A3 (en)	2005-02-10
CA2525970C (en)	2011-03-22
JP4971794B2 (ja)	2012-07-11
DE602004022284D1 (de)	2009-09-10
DK1628663T3 (da)	2010-03-08

Legal Events

Date	Code	Title	Description
2010-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE492279T1 (de)	2011-01-15	Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
EP0792156A4 (de)	2000-03-01	Verfahren zur vorbeugung oder behandlung von vaskulären hämorragien und der alzheimerischen krankheit
DE60227658D1 (de)	2008-08-28	Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
PH12021553223A1 (en)	2022-10-17	IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
ATE348829T1 (de)	2007-01-15	Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
ATE409176T1 (de)	2008-10-15	1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
IL225192A (en)	2017-12-31	Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
ATE412415T1 (de)	2008-11-15	Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
UY28011A1 (es)	2004-04-30	Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
BRPI0712322A2 (pt)	2012-02-22	compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
WO2006001877A3 (en)	2006-02-16	Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
DE602004024565D1 (de)	2010-01-21	Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
WO2003092617A3 (en)	2004-05-13	Combinations for the treatment of inflammatory skin disorders
DE602004022284D1 (de)	2009-09-10	Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
PH12021553232A1 (en)	2022-09-05	2h-indazole derivatives and their use in the treatment of disease
WO2005014041A3 (en)	2005-05-06	Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
DE60312505D1 (de)	2007-04-26	Injektion aus ixeris sonchifolia zur behandlung von kardiozerebralen gefässerkrankungen und funduserkrankungen sowie herstellungsverfahren dafür
BR0306855A (pt)	2005-04-05	Método para o tratamento de distúrbios cognitivos
ATE285773T1 (de)	2005-01-15	Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE494903T1 (de)	2011-01-15	Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
DE602005008417D1 (de)	2008-09-04	Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
IL176453A0 (en)	2006-10-05	Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
Estrada et al.	2016	Transcranial magnetic stimulation on rodent models
DE60131100D1 (de)	2007-12-06	Verfahren zur behandlung bestimmter augenkrankheiten
UA23763A (uk)	1998-06-16	Спосіб одержаhhя лікувальhого засобу при захворюваhhях, що супроводжуються порушеhhям фуhкцій цеhтральhої hервової системи